Lung Transplantation and the Era of the Sensitized Patient.

Journal Article (Journal Article;Review)

Long term outcomes in lung transplant are limited by the development of chronic lung allograft dysfunction (CLAD). Within the past several decades, antibody-mediated rejection (AMR) has been recognized as a risk factor for CLAD. The presence of HLA antibodies in lung transplant candidates, "sensitized patients" may predispose patients to AMR, CLAD, and higher mortality after transplant. This review will discuss issues surrounding the sensitized patient, including mechanisms of sensitization, implications within lung transplant, and management strategies.

Full Text

Duke Authors

Cited Authors

  • Young, KA; Ali, HA; Beermann, KJ; Reynolds, JM; Snyder, LD

Published Date

  • 2021

Published In

Volume / Issue

  • 12 /

Start / End Page

  • 689420 -

PubMed ID

  • 34122454

Pubmed Central ID

  • PMC8187850

Electronic International Standard Serial Number (EISSN)

  • 1664-3224

Digital Object Identifier (DOI)

  • 10.3389/fimmu.2021.689420


  • eng

Conference Location

  • Switzerland